SUNDAY, JUNE 17, 2018

Takeda speeds new treatments for neglected tropical diseases

Takeda speeds new treatments for neglected tropical diseases.
Takeda speeds new treatments for neglected tropical diseases. | Courtesy of
Takeda Pharmaceutical Company Limited recently announced that it has joined WIPO Re:Search, which is a consortium that is dedicated to speeding the research and development of new vaccines, drugs and diagnostics for neglected tropical diseases, tuberculosis (TB) and malaria.

The goal of the consortium is to further product development by fostering better collaboration while also building concrete contributions to improve healthcare foundations within developing nations.

"Takeda's participation in the consortium demonstrates our commitment to supporting better access to medicines for people around the world, including those in emerging markets and developing counties," Isabel Torres, director of Access to Medicines, Takeda, said. "We will continue our efforts to contribute to global health through WIPO Re:Search, together with a number of other Access to Medicines programs such as the Global Health Innovative Technology Fund."

Originally founded in 2011, WIPO Re:Search was established by the World Intellectual Property Organization (WIPO) and BIO Ventures for Global Health (BGH), as well as other top pharmaceutical companies and famous public sector research organizations.

WIPO uses a public database to offer its intellectual property assets and resources pertaining to expertise, compounds, know-how and more with a royalty-free license. Various people gain access to the databased through qualified research institutions as well as non-profit organizations. Through sharing information on the database, the organizations hope to create innovative treatments for patients around the world.

Organizations in this Story

Takeda Pharmaceutical Company

Want to get notified whenever we write about Takeda Pharmaceutical Company ?
Next time we write about Takeda Pharmaceutical Company, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.